Andrew Koeck, President
The pharmaceuticals industry is controversial, lucrative, and ubiquitous. While there’s no denying it saves millions of lives each year, the industry also often encounters several headwinds, including opioid addiction, product safety issues, and allegations of collusion. These and other issues keep the industry firmly at the bottom of most opinion polls gauging the public’s opinion of various industry sectors.
Indeed, maintaining a positive and trustworthy reputation is no easy task for pharma companies. That’s why most pharma companies with multiple brands and therapeutic lines leverage public relations (PR) to translate their value proposition to key audiences. In many cases, however, since each specific pharma product typically has unique PR requirements, each line of business (LOB) often ends up employing a different PR agency for media monitoring, media analysis, and daily news briefs. Managing these different vendors very often becomes a huge hurdle leading to siloed media data, process inefficiencies, methodology and data inconsistencies, erratic scheduling, and higher costs.
And because media monitoring, daily news brief curation, and media analysis fall outside the core competencies of most PR firms, these firms generally rely on undertrained staff and automated, keyword-driven media monitoring tools to deliver these products – leading to data inaccuracy.
Fullintel is a Cambridge, Mass.-based media intelligence firm that mitigates these challenges through powerful, human-curated traditional and social media monitoring, executive news briefs, and media analysis services. “We consolidate media monitoring, daily news brief curation, and media analysis for pharmaceutical companies across all therapeutic lines under a single, unified methodology that provides economies of scale and follows industry best practices,” says President Andrew Koeck.
“We empower pharmaceutical companies with accurate, easily comparable, and consistent global media data and enable their PR agencies to drive their daily PR agenda through daily, actionable news briefs.”
The company also provides monthly deep-dive analysis reports by industry-certified staff, offering a big-picture view of sentiment, trends, key influencers, and other metrics. This helps agencies perform better media engagement and campaigns through consistent, reliable data.
Fullintel deploys an expert team of media analysts and monitoring specialists with longstanding experience in media intelligence and the pharmaceutical industry, providing economies of scale through centralized media monitoring and media tagging, instead of the same article being reviewed and assessed multiple times by each LOB. This is complemented by an automated software-as-a-service (SaaS) dashboard, allowing LOB owners and the corporate office to drill down into media performance by the business unit based on a consistent approach and apples-to-apples data (users can view the raw data as well). A single, flexible, pre-approved master services agreement also makes ad-hoc reporting requests faster and easier.
We consolidate media monitoring, daily news brief curation, and media analysis for pharmaceutical companies across all therapeutic lines under a single, unified methodology that provides economies of scale and follows industry best practices,” says President Andrew Koeck.
Fullintel is a trusted partner of several pharmaceutical and healthcare companies, including one Fortune 50 company that saved 50 percent of its media monitoring, daily news briefs, and monthly media analysis costs after consolidating its previously siloed media intelligence approach. Fullintel now provides one consolidated dataset across the enterprise, saving the company hundreds of thousands of dollars per year through a single source of media data truth, consistent reporting metrics, and standardized reporting format.
But despite its success, the company isn’t standing still: Fullintel will roll out a new, AI-powered solution to augment its award-winning human media monitoring, news brief curation, and media measurement capabilities in early 2022. Designed to identify and predict emerging PR risks and opportunities through trending stories and emerging narratives, the platform provides 24/7/365 predictive media intelligence and is supported by expert analysts on call around the clock to respond to any pressing issue.
“The new AI product combined with our industry-leading human curation will be an even more powerful tool for PR and corporate teams at pharmaceutical companies, helping them manage any scenario – including a crisis – helping them get their media mentions back to a neutral or positive tone faster,” adds Koeck.